Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc is positioned for significant growth in the upcoming quarters, supported by strong commercial momentum and an anticipated increase in sales due to a permanent J-code becoming effective on April 1, 2026. Management has provided guidance indicating first quarter 2026 product sales are expected to exceed $18 million, reflecting a remarkable sequential growth of over five-fold. The company's innovative technology platforms and active expansion efforts in treatment centers further enhance its potential for revenue acceleration and overall positive financial outlook.

Bears say

Precigen Inc. reported fourth-quarter sales of $3.4 million, significantly underperforming against the consensus estimate of $8.3 million. The company's net loss was $0.04 per diluted share, which, while slightly better than the expected loss of $0.08 per share, still reflects ongoing financial challenges. The substantial discrepancy between actual sales and expectations indicates potential difficulties in market acceptance or execution of its business strategy, contributing to a negative outlook on the company's stock.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.